The changes of serum angiotensin-converting enzyme 2 in patients with pulmonary arterial hypertension due to congenital heart disease

Cardiology (Switzerland)

Volumn 124, Issue 4, 2013, Pages 208-212

  Dai, Hai Long ^a   Guo, Yue ^a   Guang, Xue Feng ^a   Xiao, Zhi Cheng ^a,b   Zhang, Ming ^a   Yin, Xiao Long ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Angiotensin converting enzyme 2; Congenital heart disease; Pulmonary arterial hypertension

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2;

ADULT; ARTICLE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN CONTENT; PULMONARY HYPERTENSION;

EID: 84875686064     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000346884     Document Type: Article

References (19)

1. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (1 suppl):S43-S54.
2. Trojnarska O, Plaskota K: Therapeutic methods used in patients with Eisenmenger syndrome. Cardiol J 2009; 16: 500-506.
3. Vaz-Silva I, Carneiro MM, Ferreria MC, Pinheiro SV, Silva DA, Silva-Fillo AL, Witz CA, Reis AM, Santos RA, Reis FM: The vasoactive peptide angiotensin- (1-7), its receptor Mas and the angiotensin-converting enzyme type 2 are expressed in the human endothelium. Reprod Sci 2009; 16: 247-256.
4. Imai Y, Kuba K, Ohto-Nakanishi T, Penninger JM: Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J 2010; 74: 405-410.
5. Raizada MK, Ferreira AJ: ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 2007; 50: 112-119.
6. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, Castellano RK, Ostrov DA, Oh SP, Katovich MJ, Raizada MK: Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 1048-1054.
7. Shenoy V, Qi Y, Katovich MJ, Raizada MK: ACE2, a promising therapeutic target for pulmonary hypertension. Curr Opin Pharmacol 2011; 11: 150-155.
8. Johnson JA, West J, Maynard KB, Hemnes AR: ACE2 improves right ventricular function in a pressure overload model. PLoS One 2011; 6:e20828.
9. Li G, Xu YL, Ling F, Liu AJ, Wang D, Wang Q, Liu YL: Angiotensin-converting enzyme 2 activation protects against pulmonary arterial hypertension through improving early endothelial function and mediating cytokines levels. Chin Med J (Engl) 2012; 125: 1381-1388.
10. Yamazato Y, Ferreira AJ, Hong KH, Sriramula S, Francis J, Yamazato M, Yuan L, Bradford CN, Shenoy V, Oh SP, Katovich MJ, Raizada MK: Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer. Hypertension 2009; 54: 365-371.
11. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Diez-Freire C, Dooies A, Jun JY, Sriramula S, Mariappan N, Pourang D, Venugopal CS, Francis J, Reudelhuber T, Santos RA, Patel JM, Raizada MK, Katovich MJ: The ACE2/ Ang- (1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2010; 182: 1065-1072.
12. Kleinsasser A, Pircher I, Treml B, Schwienbacher M, Schuster M, Janzek E, Loibner H, Penninger JM, Loeckinger A: Recombinant angiotensin-converting enzyme 2 suppresses pulmonary vasoconstriction in acute hypoxia. Wilderness Environ Med 2012; 23: 24-30.
13. Treml B, Neu N, Kleinsasser A, Gritsch C, Finsterwalder T, Geiger R, Schuster M, Janzek E, Loibner H, Penninger J, Loeckinger A: Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide induced lung injury in piglets. Crit Care Med 2010; 38: 596-601.
14. Rondelet B, Kerbaul F, Van Beneden R, Hubloue I, Huez S, Fesler P, Remmelink M, Brimioulle S, Salmon I, Naeije R: Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 2005; 289:H2319-H2324.
15. Farber HW, Loscalzo J: Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665.
16. Smadja DM, Gaussem P, Mauge L, Israel-Biet D, Dignat-George F, Peyrard S, Agnoletti G, Vouhe PR, Bonnet D, Levy M: Circulating endothelial cells: a newcandidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 2009; 119: 374-381.
17. Schrier RW, Bansal S: Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure? Clin J Am Soc Nephrol 2008; 3: 1232-1237.
18. Hayashi N, Yamamoto K, Ohishi M, Tatara Y, Takeya Y, Shiota A, Oguro R, Iwamoto Y, Takeda M, Rakugi H: The counterregulating role of ACE2 and ACE2-mediated angiotensin 1-7 signaling against angiotensin II stimulation in vascular cells. Hypertens Res 2010; 33: 1182-1185.
19. Li J, Gao J, Xu YP, Zhou TL, Jin YY, Lou JN: Expression of severe acute respiratory syndrome coronavirus receptors, ACE2 and CD209L in different organ derived microvascular endothelial cells. Zhonghua Yi Xue Za Zhi 2007; 87: 833-837.